A Phase 1 Randomized, Open-Label, Two-Period,Two-Sequence Crossover Study to Evaluate the Relative Oral Bioavailability of Levoketoconazole and Ketoconazole Tablets in Healthy Subjects

This is a phase 1, randomized, open-label, single-dose, two-period, two-sequence crossover study in healthy male and female subjects to evaluate the relative oral bioavailability of levoketoconazole tablets (the test drug) and ketoconazole tablets (the reference drug product).

开始日期2019-12-16

申办/合作机构

Cortendo AB

NCT03880825

/ Completed临床1期

A Phase I Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Study to Evaluate the Effect of Levoketoconazole on the Single-Dose Pharmacokinetics of Metformin in Healthy Subjects

This is a phase I, open-label, fixed-sequence drug-drug interaction study to evaluate the effect of levoketoconazole on the single-dose PK of metformin in health subjects.

开始日期2019-03-28

申办/合作机构

Cortendo AB

NCT03621280

/ Completed临床3期

An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

This is a long-term, open-label extension study of levoketoconazole in subjects with endogenous Cushing's Syndrome.

开始日期2019-01-07

申办/合作机构

Cortendo AB

100 项与左旋酮康唑相关的临床结果

登录后查看更多信息

100 项与左旋酮康唑相关的转化医学

登录后查看更多信息

100 项与左旋酮康唑相关的专利（医药）

登录后查看更多信息

项与左旋酮康唑相关的文献（医药）

2024-07-01·Indian Journal of Endocrinology and Metabolism

Efficacy and Safety of Levoketoconazole in Managing Cushing’s Syndrome: A Systematic Review

Review

作者: Dutta, Deep ; Raizada, Nishant ; Patra, Shinjan ; Nagendra, Lakshmi

AbstractNo systematic review has holistically analysed the efficacy and safety of levoketoconazole, a novel purified 2S,4R enantiomer of ketoconazole, believed to be 15- to 25-fold more potent than ketoconazole for managing Cushing’s syndrome (CS). We undertook this meta-analysis to address this knowledge gap. Electronic databases were searched for studies involving patients with CS receiving levoketoconazole in the intervention arm. The primary outcome was to evaluate changes in mean 24-hour urine-free cortisol (mUFC) levels. Secondary outcomes were to evaluate alterations in cortisol and adverse events. SONICS study showed that normalisation of mUFC was seen in 61%, 55%, and 41% of the patients at the end of 6, 9, and 12 months therapy, respectively. The LOGICs study showed that withdrawal of levoketoconazole was associated with a significant increase in mUFC from 81.3 ± 35.7 to 220.8 ± 333.5 nmol/24h. The late-night salivary-cortisol (LNSC) increase during the drug withdrawal phase was 2.6 nmol/L in the placebo group (PG) compared to 2.2 nmol/L in the levoketoconazole group (LG) (P < 0.05). Re-initiation of levoketoconazole in original LG was associated with a decrease in mUFC from 224.3 ± 341.3 to 135.6 ± 87.3 nmol/24h. Initiation of levoketoconazole in the original PG was associated with a decrease in mUFC from 537.9 ± 346.0 to 141.3 ± 130.3 nmol/24h. Normalisation of mUFC was observed in 50.0% patients in LG compared to 4.5% in the placebo group. The median time for the response was 25 days. The median time to loss of therapeutic response was significantly shorter for PG (24 days) compared to LG (62 days) (P < 0.0001). Levoketoconazole has good efficacy and safety in CS. Bigger and longer studies are warranted to establish its superiority over ketoconazole.

2023-05-30·Journal of Chromatographic Science

A New Strategy for the Software-Assisted LC Separations of Ketoconazole and Its Impurities

Article

作者: Bonde, Chandrakant ; Belemkar, Sateesh ; Agrawal, Roopali

AbstractAnalytical quality by design and the use of dissimilar chromatographic systems can be employed to accelerate chromatographic separations. Herein, a software (S-Matrix)-assisted platform was used to proficiently screen, optimize and select the optimal parameters for the chromatographic separation of ketoconazole and its related impurities. This approach evaluated the various chromatographic parameters in a stepwise manner based on the statistical tools and provided an in-depth understanding of the critical parameters influencing the peak selectivities and separations. It was demonstrated that dissimilar conditions, such as different stationary phases, mobile phase pH and organic modifiers (i.e., critical method variables), can improve the peak resolution, while the critical quality attributes can provide conditions appropriate for quantification purposes via a quality target analytical method. Furthermore, an orthogonal method was established to support the primary method. The orthogonality between the two methods was defined by the correlation matrix between the two systems using the Pearson correlation coefficient and was found to be 0.12. Using the optimized method, the primary method was validated as per International Council for Harmonization in the range of 0.05–1.0% for impurities and 80.0–120.0% for ketoconazole, thereby indicating the suitability of the method for use in quality control laboratories.

2022-12-01·European Journal of Endocrinology

Levoketoconazole treatment in endogenous Cushing's syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes

Article

作者: Auchus, Richard J ; Buchfelder, Michael ; Geer, Eliza B ; Pivonello, Rosario ; Greenman, Yona ; Kennedy, Laurence ; Feldt-Rasmussen, Ulla ; Cohen, Fredric ; Zacharieva, Sabina ; Fleseriu, Maria ; Heaney, Anthony P ; Biller, Beverly M K ; Salvatori, Roberto

AbstractObjectiveThis extended evaluation (EE) of the SONICS study assessed the effects of levoketoconazole for an additional 6 months following open-label, 6-month maintenance treatment in endogenous Cushing's syndrome.Design/MethodsSONICS included dose-titration (150–600 mg BID), 6-month maintenance, and 6-month EE phases. Exploratory efficacy assessments were performed at months 9 and 12 (relative to the start of maintenance). For pituitary MRI in patients with Cushing's disease, a threshold of ≥2 mm denoted change from baseline in the largest tumor diameter.ResultsSixty patients entered EE at month 6; 61% (33/54 with data) exhibited normal mean urinary free cortisol (mUFC). At months 9 and 12, respectively, 55% (27/49) and 41% (18/44) of patients with data had normal mUFC. Mean fasting glucose, total and LDL-cholesterol, body weight, BMI, abdominal girth, hirsutism, CushingQoL, and Beck Depression Inventory-II scores improved from the study baseline at months 9 and 12. Forty-six patients completed month 12; four (6.7%) discontinued during EE due to adverse events. The most common adverse events in EE were arthralgia, headache, hypokalemia, and QT prolongation (6.7% each). No patient experienced alanine aminotransferase or aspartate aminotransferase >3× upper limit of normal, Fridericia-corrected QT interval >460 ms, or adrenal insufficiency during EE. Of 31 patients with tumor measurements at baseline and month 12 or follow-up, the largest tumor diameter was stable in 27 (87%) patients, decreased in one, and increased in three (largest increase 4 mm).ConclusionIn the first long-term levoketoconazole study, continued treatment through a 12-month maintenance period sustained the early clinical and biochemical benefits in most patients completing EE, without new adverse effects.

项与左旋酮康唑相关的新闻（医药）

2025-01-21

·PRNewswire

The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a ready-to-use formulation CHICAGO and ARLINGTON, Va., Jan. 21, 2025 /PRNewswire/ -- The American Diabetes Association® (ADA) and Xeris Pharmaceuticals® (Xeris BioPharma Holdings, Inc.), a national supporter of the ADA, are pleased to announce a multi-year strategic partnership to reinforce the importance of prescribing glucagon, preferably ready-to-use, for all individuals with diabetes who are treated with insulin and/or insulin secretagogues or those at high risk of hypoglycemia (low blood glucose, also called low blood sugar), in line with the ADA's recently updated Standards of Care in Diabetes—2025 (Standards of Care).1 "Severe hypoglycemia is life-threatening, and people with diabetes on blood glucose-lowering medication are at risk for hypoglycemia. Thus, we must act with urgency to educate people about the importance of having a treatment plan in place that includes having glucagon on hand," said Charles "Chuck" Henderson, the ADA's chief executive officer. "Through this important partnership, we can save lives by ensuring individuals with diabetes who are treated with insulin have access to glucagon, preferably a ready-to-use formulation, so they can make a plan and be ready." It is estimated that up to 46% of people with type 1 diabetes and 21% of those with type 2 diabetes using insulin experience at least one severe hypoglycemia event each year.2 Hypoglycemia is conservatively responsible for more than 202,000 emergency department visits annually with approximately 25% being admitted to the hospital.3 This is unacceptable. More needs to be done to protect people at risk for severe hypoglycemia. The ADA, with support from Xeris, seeks to rectify the low rates of appropriate glucagon prescriptions by developing education materials and training resources for health care professionals and people living with diabetes, as well as through a national awareness campaign to educate people on who is at risk for severe hypoglycemia and should have glucagon, preferably ready-to-use, as a safety net. "Severe hypoglycemia is associated with up to a three-time increased risk of death in people with diabetes.4,5,6 Xeris is proud to collaborate with the ADA to urge adoption of their strengthened clinical practice recommendations around the treatment of severe hypoglycemia," said John Shannon, Xeris' CEO. "The stakes are too high for so many patients at risk to be without a safety net. Our mutual commitment is to fight for all patients living with diabetes and ensure that they can face severe low blood glucose emergencies with confidence by always having a ready-to-use glucagon on hand." To learn more about the importance of severe hypoglycemia, readiness and treatment options, visit diabetes.org/severehypo. About the American Diabetes Association The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to end diabetes and helping people thrive. For 84 years, the ADA has driven discovery and research to prevent, manage, treat, and ultimately cure diabetes. There are 136 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we're fighting for them all. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), and Instagram (@AmDiabetesAssn). To learn more about how we are advocating for everyone affected by diabetes, visit us on X (@AmDiabetesAssn). About Xeris Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing's syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism as well as multiple early-stage programs leveraging Xeris' technology platforms, XeriSol® and XeriJect®, for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit , or follow us on X, LinkedIn, or Instagram. American Diabetes Association Professional Practice Committee; 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025. Diabetes Care 1 January 2025; 48 (Supplement_1): S128–S145. Stuckey HL, Desai U, King SB, et al. The experience of a severe hypoglycaemic event from the perspective of people with diabetes and their caregivers: "What am I going to do?". Diabet Med. 2022;39(4):e14745. doi:10.1111/dme.14745 Centers for Disease Control and Prevention. National Diabetes Statistics Report. Accessed January 8, 2025. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384-1395. doi:10.2337/dc12-2480 McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35(9):1897-1901. doi:10.2337/dc11-2054 Zoungas S, Patel A, Chalmers J, et al. Severe Hypoglycemia and Risks of Vascular Events and Death. N Engl J Med. 2010;363(15):1410-1418. doi: 10.1056/NEJMoa1003795. Contact: Virginia Cramer, (703) 253-4927 [email protected] SOURCE American Diabetes Association WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期

2025-01-10

·xerispharma.com

Xeris Expects to Exceed Full-Year 2024 Financial Guidance

Full-year 2024 total revenue projected to be $203 million, exceeding previous guidance of $198-$202 million Year-end 2024 cash position expected to be over $71 million, generating positive cash flow in the fourth quarter Recorlev® net revenue Q4 2024 anticipated to increase by approximately $5 million or 28% sequentially 2024 financial results and 2025 outlook expected on March 6, 2025 CHICAGO--(BUSINESS WIRE)--Jan. 10, 2025-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced it expects to generate total 2024 revenue of $203 million, which will exceed previously announced 2024 total revenue guidance of $198 million to $202 million. The Company also anticipates ending 2024 with over $71 million in cash, cash equivalents, and short-term investments, generating positive cash flow in the fourth quarter. “We achieved another record quarter of exceptional total revenue growth with revenues expected to be $60 million for the fourth quarter and $203 million for the full year representing growth of 35% and 24%, respectively. These impressive results are driven by accelerating demand for Recorlev and continued strong Gvoke demand,” said John Shannon, CEO of Xeris. “Our focus remains on continuing to drive exceptional product revenue growth and advancing our robust pipeline - namely our Phase 3 ready, XP-8121 program. With our commercial engine leading the way and our strong balance sheet, we are well positioned for a transformational 2025.” Other Fourth Quarter 2024 Updates Recorlev® achieved record number of new starts and referrals. Gvoke® ended the year with approximately 35% market share. Keveyis® maintained a similar number of patients on therapy as Q3 2024. Beta Bionics, Inc.: Xeris successfully formulated a unique XeriSol® formulation of glucagon for bi-hormonal pumps and pump systems. This triggered a milestone payment of $3 million in the fourth quarter. Amgen: Amgen chose to terminate its exclusive worldwide license agreement with Xeris following a broader company portfolio assessment. Their decision was not related to the performance of the XeriJect® formulation technology. The termination will not have a material impact on Xeris’ outlook. About Xeris Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram. Forward-Looking Statements Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc. including statements regarding the financial outlook for 2024, including quarterly product revenue, projections regarding year-end 2024 cash estimates and total revenue, company performance in 2025, the potential for growth of revenue, the market, demand and therapeutic potential of its products and product candidates, the potential utility of its formulation platforms, the advancement of its pipeline (including XP-8121), the impact of the termination of the Amgen license agreement on our outlook, the timing of the release of our financial results and outlook, and other statements containing the words “will,” “would,” “continue,” “expect,” “should,” “anticipate” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, and its and collaborators’ ability to protect its intellectual property and proprietary technology. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris’ filings, including those other risk factors identified in the “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections of Xeris' Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC), the contents of which are not incorporated by reference into, nor do they form part of, this communication. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.xerispharma.com, for a discussion of these and other risks and uncertainties. Forward-looking statements in this communication are based on information available to us, as of the date of this communication and, while we believe our assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, we do not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. View source version on businesswire.com: https://www.businesswire.com/news/home/20250110463157/en/ Allison Wey Senior Vice President, Investor Relations and Corporate Communications awey@xerispharma.com Source: Xeris Biopharma Holdings, Inc.

引进/卖出财报临床3期

2024-11-26

·xerispharma.com

Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Nov. 26, 2024-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 at 8:00am Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Xeris’ Investor Relations website at www.xerispharma.com. A replay of the webcast will be available for 30 days. About Xeris Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs to bring new products forward using its proprietary formulation technology platforms, XeriSol® and XeriJect®, supporting long-term product development and commercial success. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram. View source version on businesswire.com: https://www.businesswire.com/news/home/20241125772487/en/ Investor Contact Allison Wey Senior Vice President, Investor Relations and Corporate Communications awey@xerispharma.com Source: Xeris Biopharma

100 项与左旋酮康唑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10950	左旋酮康唑	-	DB05667

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
内源性库欣综合征	美国	Strongbridge Ireland Ltd.	2021-12-30

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
2型糖尿病	临床2期	澳大利亚	DiObex, Inc.	2008-01-01
2型糖尿病	临床2期	美国	DiObex, Inc.	2008-01-01
2型糖尿病	临床2期	新西兰	DiObex, Inc.	2008-01-01
内源性库欣综合征	药物发现	丹麦	Cortendo AB	2014-08-01
内源性库欣综合征	药物发现	捷克	Cortendo AB	2014-08-01
内源性库欣综合征	药物发现	加拿大	Cortendo AB	2014-08-01
内源性库欣综合征	药物发现	德国	Cortendo AB	2014-08-01
内源性库欣综合征	药物发现	土耳其	Cortendo AB	2014-08-01
内源性库欣综合征	药物发现	比利时	Cortendo AB	2014-08-01
内源性库欣综合征	药物发现	塞尔维亚	Cortendo AB	2014-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01838551 (SONICS, Corporate Publications) 人工标引	临床3期	库欣综合征	92	Recorlev (Baseline mUFC≤2.5xULN)	(選鹽憲願餘醖膚糧願繭) = 糧鬱築壓鹹鹹蓋選壓鬱構觸簾齋鑰鹹顧築壓遞 (鹽鬱壓遞鏇鹹襯淵繭遞, 0.16 ~ 0.47) 更多	积极	2024-06-03
				Recorlev (Baseline mUFC>2.5 to ≤5xULN)	(選鹽憲願餘醖膚糧願繭) = 淵觸繭衊鹹鹽襯齋鏇憲構觸簾齋鑰鹹顧築壓遞 (鹽鬱壓遞鏇鹹襯淵繭遞, 0.20 ~ 0.54) 更多
ENDO2024	N/A	-	3	Levoketoconazole 150 mg BID	願簾廠願鬱網鑰鹹構醖(範構憲範衊蓋窪獵壓膚) = The other two patients are being carefully monitored for QTc abnormalities 積膚壓醖窪選鑰鑰遞壓 (範遞醖鏇廠醖願鏇膚製 ) 更多	-	2024-06-01
				Levoketoconazole 300 mg BID
SONICS Study (ENDO2024)	临床3期	-	94	Levoketoconazole (Group 2: >2.5x to ≤5x ULN)	襯夢積顧簾壓顧壓觸繭(製蓋積積鹹顧鏇築壓糧) = Group 3 had more liver-related adverse events of special interest than Group 1 or 2 (14% vs 7.9% or 3.0%) and more AEs leading to discontinuation (24% vs 12% or 16%) 膚淵夢製築顧糧選鹹膚 (網廠鏇構獵艱蓋築簾鏇 )	积极	2024-06-01
				Levoketoconazole (Group 3: >5x ULN)
Corporate Publications 人工标引	临床3期	库欣综合征	79	Levoketoconazole	鏇鏇壓鹹廠壓築製壓糧(築簾鹹廠顧壓範選觸襯) = 醖願襯積範繭遞遞壓夢膚積積鏇窪廠淵餘網衊 (鏇網構積選簾簾糧鹽壓 ) 更多	积极	2022-05-12
				Placebo	鏇鏇壓鹹廠壓築製壓糧(築簾鹹廠顧壓範選觸襯) = 簾鹽遞範獵積範窪廠衊膚積積鏇窪廠淵餘網衊 (鏇網構積選簾簾糧鹽壓 ) 更多
NCT03277690 (LOGICS, ENDO2021)	临床3期	内源性库欣综合征	84	Levoketoconazole	鬱壓築選繭醖襯積襯襯(鬱餘製製範糧遞製憲積) = 鑰壓構憲觸鏇膚願鹽遞壓襯糧膚網獵積觸築積 (獵夢顧鹹觸選糧廠夢鬱 ) 更多	积极	2021-05-03
				Placebo	鬱壓築選繭醖襯積襯襯(鬱餘製製範糧遞製憲積) = 獵簾鹽製廠製膚鑰築積壓襯糧膚網獵積觸築積 (獵夢顧鹹觸選糧廠夢鬱 ) 更多
NCT01838551 (SONICS, CTgov)	临床3期	内源性库欣综合征	94	Levoketoconazole	範膚餘廠範顧築蓋夢積(積餘積願夢顧艱淵襯構) = 衊繭顧觸艱積網鑰獵網憲觸餘蓋淵鏇襯構艱壓 (獵醖壓構鬱觸築糧襯憲, 範膚願鬱糧願夢壓窪製 ~ 蓋選繭餘網鏇鹹夢蓋窪) 更多	-	2021-04-19
NCT01838551 (SONICS, Pubmed \| Front Endocrinol (Lausanne))	临床3期	糖尿病 \| 库欣综合征	94	Levoketoconazole (Patients with DM)	淵構簾糧淵窪壓襯網襯(鏇膚淵築觸襯鏇範廠糧): P-Value = 0.0006 更多	-	2021-01-01
				Levoketoconazole (Patients without DM)
NCT03277690 (LOGICS, Biospace) 人工标引	临床3期	内源性库欣综合征	44	RECORLEV	憲願夢構鬱壓鏇窪憲選(膚繭顧窪構膚選顧衊構) = 憲壓餘膚顧網積獵簾顧齋鬱鑰積鑰鑰鏇鹹蓋願 (窪淵餘鑰簾衊鏇壓艱壓 ) 更多	积极	2020-09-08
				placebo	憲願夢構鬱壓鏇窪憲選(膚繭顧窪構膚選顧衊構) = 鏇簾鏇衊鏇窪衊齋憲鏇齋鬱鑰積鑰鑰鏇鹹蓋願 (窪淵餘鑰簾衊鏇壓艱壓 ) 更多
NCT01838551 (SONICS, ENDO2019)	临床3期	糖尿病 \| 库欣综合征维持	94	Levoketoconazole	(遞構鏇齋醖廠醖獵鬱窪) = 齋糧醖窪夢衊鹹齋積鏇範遞醖鑰餘膚網餘淵餘 (選範繭願構憲築築簾鬱 ) 更多	积极	2019-04-30
				Placebo	(遞構鏇齋醖廠醖獵鬱窪) = 構選憲憲簾憲壓憲鑰夢範遞醖鑰餘膚網餘淵餘 (選範繭願構憲築築簾鬱 ) 更多